Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-02-27 · accession 0001600620-26-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-02-27 | AUPH | Keenan Greg | SVP, Chief Medical Off | A - Grant | $0.00 | +40.6K | 162.5K | +33% | $0 |
| D | 2026-03-03 | 2026-02-27 | AUPH | Keenan Greg | SVP, Chief Medical Off | A - Grant | $0.00 | +67.9K | 67.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-27 | A | A | 40,586 | $0.00 | 162,518 | D | — | — | (F1) Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2026-02-27 | A | A | 67,870 | $0.00 | 67,870 | D | $13.97 · — to 2036-02-27 | 67,870 Common Stock | (F2) One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. |